On August 3, 2022, the 14th Healthy China Forum released the Top Ten New Drugs (in China) ranking, and Hansoh Pharma's Hengmu (Tenofovir Amibufenamide Tablets), as China's first original oral anti-HBV innovative drug, entered the ranking. 

Co-sponsored by People's Daily Health Client and People's Daily Health Times, the Healthy China Forum is one of the earliest, best, most influential, and most authoritative forums themed on "Healthy China" in China's healthcare sector. It took more than seven months to determine the various rankings at the 14th Healthy China Forum, and each ranking was determined from the dimensions of annual innovation, clinical breakthrough, drug benefit, and public attention. 

Hengmu is China's first original oral anti-HBV innovative drug. It started pre-clinical study in 2013 and Phase III clinical study in 2018, and was approved for marketing and included in the National Reimbursement Drug List in 2021, eliminating the lack of Chinese original drugs in this field. In July 2022, the 96-week data from the large-scale Phase III clinical study of Hengmu was released, reaffirming its good efficacy and superior bone and kidney safety. Since its launch one year ago, Hengmu has benefited more than 100,000 patients with chronic hepatitis B, bringing significant pharmaceutical improvements to the clinical cure of hepatitis B in China and promoting academic progress in the field of liver disease. As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma focuses on the treatment of oncology, infection, CNS, metabolism and autoimmunity diseases, and is committed to improving human health through continuous innovation. It has excellent R&D strength and over 20 years of R&D experience, and has established R&D centers in Maryland, USA, and Shanghai, Lianyungang and Changzhou, China. Up to now, Hansoh Pharma has marketed six innovative drugs and formed a rich pipeline, ranked among the top 30 of China's Top 100 Companies in Pharmaceutical Industry and the top 3 of China's Best Industrial Enterprises in Pharmaceutical R&D Pipeline for consecutive years. Looking ahead, Hansoh Pharma will uphold the corporate mission to create excellence in pharmaceuticals and enhance innovation in China, accelerate the pace of scientific and technological innovation, focus on meeting the unfulfilled medical needs in clinical practice, and keep developing more innovative drugs to improve the health and quality of life of human beings and contribute to the Healthy China 2030 initiative.